Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 3/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29039016 | 0.82 | PDE2A (0.39) | HSD11B1ADORA2AADORA1PDE2APDE10A | |
| SCHEMBL30415229 | 0.82 | PDE2A (0.39) | HSD11B1ADORA2AADORA1PDE2APDE10A | |
| SCHEMBL21543544 | 0.79 | HSD11B1 (0.46) | HSD11B1HPGDKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25230310 | 0.76 | CYP1A2 (0.47) | HSD11B1HPGDKMT2AALDH1A1KDM4E | |
| SCHEMBL9140129 | 0.73 | ADORA2A (0.46) | HSD11B1ADORA2AADORA1KCNN4MBNL1 | |
| SCHEMBL23792999 | 0.72 | — | — | |
| SCHEMBL29547174 | 0.68 | ACHE (0.47) | KMT2AALDH1A1NOTUMKDM4ESMN1; SMN2 | |
| SCHEMBL197834 | 0.68 | ACHE (0.47) | KMT2AALDH1A1NOTUMKDM4ESMN1; SMN2 | |
| SCHEMBL4023321 | 0.68 | MEN1 (0.49) | KMT2AALDH1A1NOTUMKDM4ESMN1; SMN2 | |
| SCHEMBL20744323 | 0.68 | HDAC8 (0.32) | PDE2APDE10AHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HSD11B1 3503/4885ADORA2A 4604/4885ADORA1 4471/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | HSD11B1 3503/4885ADORA2A 4604/4885ADORA1 4471/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HSD11B1 3503/4885ADORA2A 4604/4885ADORA1 4471/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | HSD11B1 3503/4885ADORA2A 4604/4885ADORA1 4471/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HSD11B1 3503/4885ADORA2A 4604/4885ADORA1 4471/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HSD11B1 3503/4885ADORA2A 4604/4885ADORA1 4471/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | HSD11B1 3503/4885ADORA2A 4604/4885ADORA1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.